Jonathan Wolleben

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Wolleben, carries an average stock price target met ratio of 22.85% that have a potential upside of 41.5% achieved within 158 days. Previously, Jonathan Wolleben worked at JMP.

Jonathan Wolleben’s has documented 350 price targets and ratings displayed on 18 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ALT, Altimmune at 02-Apr-2025.

Wall Street Analyst Jonathan Wolleben

Analyst best performing recommendations are on PTGX (PROTAGONIST THERAPEUTICS).
The best stock recommendation documented was for OCUL (OCULAR THERAPEUTIX) at 9/29/2020. The price target of $16 was fulfilled within 57 days with a profit of $8.19 (104.87%) receiving and performance score of 18.4.

Average potential price target upside

of $109.8 (73.38%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $21.86 (92.42%) on CRNX (CRINETICS PHARMACEUTICALS).
of $12.36 (144.04%) on PHVS (PHARVARIS BV).

ALT Altimmune CLSD Clearside Biomedical CRNX Crinetics Pharmaceuticals DBVT DBV Technologies LRMR Larimar Therapeutics OCUL Ocular Therapeutix PRQR ProQR Therapeutics BV BCRX BioCryst Pharmaceuticals RLYB Rallybio Corp PHVS Pharvaris BV MDGL Madrigal Pharmaceuticals AURA Aura Biosciences PTGX Protagonist Therapeutics ALLK Allakos MIRM Mirum Pharmaceuticals SPRB Spruce Biosciences RYTM Rhythm Pharmaceuticals SVRA Savara

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Patrick Trucchio (HC WAINWRIGHT)